Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/3098% above fair value
$3.84−0.15 (-3.76%)
Close on Nov 16, 2026Market cap $1.35BP/E –Yield –
Nuvation Bio total assets
Total assets on the balance sheet at the end of each period.
Nuvation Bio's total assets was $744.50M at Jun 30, 2026. For fiscal 2025 it was $594.82M, up 10.0% from the year before. The highest annual figure on record is $776.15M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $594.82M | +10.0% |
| FY2024 | Dec 31, 2024 | $540.63M | -13.0% |
| FY2023 | Dec 31, 2023 | $621.48M | -7.5% |
| FY2022 | Dec 31, 2022 | $672.14M | -13.4% |
| FY2021 | Dec 31, 2021 | $776.15M | +249.9% |
| FY2020 | Dec 31, 2020 | $221.79M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $744.50M | +15.0% |
| Q1 FY2026 | Mar 31, 2026 | $610.24M | +23.9% |
| Q4 FY2025 | Dec 31, 2025 | $594.82M | +10.0% |
| Q3 FY2025 | Sep 30, 2025 | $601.56M | +5.2% |
| Q2 FY2025 | Jun 30, 2025 | $647.23M | +8.8% |
| Q1 FY2025 | Mar 31, 2025 | $492.49M | -19.7% |
| Q4 FY2024 | Dec 31, 2024 | $540.63M | -13.0% |
| Q3 FY2024 | Sep 30, 2024 | $571.58M | -9.4% |
| Q2 FY2024 | Jun 30, 2024 | $594.80M | -7.3% |
| Q1 FY2024 | Mar 31, 2024 | $613.13M | -6.7% |
| Q4 FY2023 | Dec 31, 2023 | $621.48M | -7.5% |
| Q3 FY2023 | Sep 30, 2023 | $630.87M | -8.1% |
| Q2 FY2023 | Jun 30, 2023 | $641.41M | -10.9% |
| Q1 FY2023 | Mar 31, 2023 | $657.06M | -12.6% |
| Q4 FY2022 | Dec 31, 2022 | $672.14M | -13.4% |
| Q3 FY2022 | Sep 30, 2022 | $686.49M | -14.0% |
| Q2 FY2022 | Jun 30, 2022 | $719.74M | -11.6% |
| Q1 FY2022 | Mar 31, 2022 | $751.81M | -9.6% |
| Q4 FY2021 | Dec 31, 2021 | $776.15M | +249.9% |
| Q3 FY2021 | Sep 30, 2021 | $797.79M | +448.3% |
| Q2 FY2021 | Jun 30, 2021 | $814.26M | +475757.2% |
| Q1 FY2021 | Mar 31, 2021 | $832.06M | – |
| Q4 FY2020 | Dec 31, 2020 | $221.79M | – |
| Q3 FY2020 | Sep 30, 2020 | $145.50M | – |
| Q2 FY2020 | Jun 30, 2020 | $171.12K | – |
See a number that looks wrong?